ERBB2 and breast carcinoma: And the gap was especially striking for triple‐negative breast cancer (adjusted OR 3.4, 1.5–7.5), followed by HER2‐enriched breast cancer (adjusted OR 2.1, 1.2–3.6; Figure 2C, Table 2).